TY - JOUR
T1 - Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor
AU - Acquazzino, Melissa A.
AU - Fischer, Ryan T.
AU - Langnas, Alan Norman
AU - Coulter, Donald W
PY - 2013/8
Y1 - 2013/8
N2 - AIHA is a rare and serious complication of solid organ transplantation. Herein, we report four cases of warm or mixed AIHA in pediatric patients following combined liver, small bowel and pancreas transplant. The hemolysis was refractory to multiple treatment modalities including steroids, rituximab, IVIG, plasmapheresis, cytoxan, discontinuation of prophylactic penicillin, and a change in immunosuppression from tacrolimus to cyclosporine. All patients had resolution or marked improvement of hemolysis after discontinuation of maintenance of CNI and initiation of sirolimus immunosuppression. One patient developed nephrotic syndrome but responded to a change in immunosuppression to everolimus. Three of the four patients continue on immunosuppression with sirolimus or everolimus without further hemolysis, evidence of rejection or medication side effects. Based on our experience and review of similar cases in the literature, we have proposed a treatment algorithm for AIHA in the pediatric intestinal transplant patient population that recommends an early change in immunosuppressive regimen from CNIs to sirolimus therapy.
AB - AIHA is a rare and serious complication of solid organ transplantation. Herein, we report four cases of warm or mixed AIHA in pediatric patients following combined liver, small bowel and pancreas transplant. The hemolysis was refractory to multiple treatment modalities including steroids, rituximab, IVIG, plasmapheresis, cytoxan, discontinuation of prophylactic penicillin, and a change in immunosuppression from tacrolimus to cyclosporine. All patients had resolution or marked improvement of hemolysis after discontinuation of maintenance of CNI and initiation of sirolimus immunosuppression. One patient developed nephrotic syndrome but responded to a change in immunosuppression to everolimus. Three of the four patients continue on immunosuppression with sirolimus or everolimus without further hemolysis, evidence of rejection or medication side effects. Based on our experience and review of similar cases in the literature, we have proposed a treatment algorithm for AIHA in the pediatric intestinal transplant patient population that recommends an early change in immunosuppressive regimen from CNIs to sirolimus therapy.
KW - calcineurin inhibition
KW - hemolytic anemia
KW - intestinal transplant
KW - mTOR inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84879888547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879888547&partnerID=8YFLogxK
U2 - 10.1111/petr.12101
DO - 10.1111/petr.12101
M3 - Article
C2 - 23730873
AN - SCOPUS:84879888547
SN - 1397-3142
VL - 17
SP - 466
EP - 471
JO - Pediatric Transplantation
JF - Pediatric Transplantation
IS - 5
ER -